Oy LEIRAS Finland Ab is part of the European Nycomed Group. The roots of Leiras are deep in Finland and since 1946 the company has been called Leiras. Over the decades, we have worked in close cooperation with Finnish healthcare professionals and have established a well-known position as a reliable and competent partner for the medical and pharmaceutical community in our country. Threfore we are  using name LEIRAS, although we are fully owned affiliate by Nycomed group.

Our position (among top 10 players) on the Finnish market is based not only on the long history and strong Leiras brand, but also on our skills in successfully introducing several products from different licensors. We are committed to cooperating closely with our licensors in order to make every product a success in Finland. Here our in-depth market knowledge and experience of working with a variety of licensors is a key factor in our success.

Our strong areas with dedicated sales force and marketing networks cover GPs, hospital specialists and pharmacies in the following therapy groups: * cardiovascular diseases * type 2 diabetes * systemic allergy * osteoporosis & arthrosis * pain management * special products for hospital usage (i.e. , soft tissue surgery, endocrinology and gastroenterology)

In Self Care area, we are  the third biggest marketer in Finland, with products for cough & cold, constipation and minerals & vitamins are our strongest areas.

We are one of the biggest subsidiaries of Nycomed. In 2008 we were ranked number eight in terms of revenue and number three in terms of volume in the Finnish pharmaceutical market Our revenue was around EURO 67 million. We employ 140 people, of which over 50 are working in marketing and sales.

Nycomed is a pharmaceutical company dedicated to meet health needs in Europe. Headquartered in Zurich, Switzerland, the company employs about 12,000 people throughout world including fast growing markets like Russia/CIS and Latin America. Nycomed is privately owned group and had a 2007 revenue of EURO 3,5 billion.

Rx portfolio: NCE´s for following segments: * Diabetes (type 2 ): DPP-IV inhibitors + other new approaches. * Cardiovascular disease: hypertension; cholesterol lowering drugs and antihypertensives * Gastroenterological disease: TNF-like products * CNS disease: epilepsy drugs, Alzheimer's disease drugs, anti-psychotics, anti-depressants, Parkinson's disease disease, * Hospital sector: - i.v. antibiotics - semi modern cancer drugs - antineoplastics (EPH 3 group L01X) - adjunctive products for cancer - immunostimulating agents, new antiemetics, immunosuppressive agents * OTC portfolio: * laxatives ie. macrogol, * smoking cessation products (chewing gums) * laxatives * cough&cold products * throath preparations * oral hair growth stimulants